Better Buy: Pfizer vs. Johnson & Johnson | The Motley Fool
LabCorp and Quest to Offer Coronavirus Tests | The Motley Fool
How will Pharma Giants Fight COVID in 2023? | by Ozios | Medium
As Patent Cliff Looms for Biopharma Giants, Smaller Biotechs Face Cash Crunch: EY's Arda Ural, PhD, discusses how the parallel challenges will shape industry growth and the pursuit of capital this year
Pharma giants gaining big in 2022
Drug Giants Look for Growth Fuel as Older Blockbusters Show Age - Bloomberg
The Tiny Giants
GSK, AstraZeneca: Will the two UK drugs giants ride the US$74bn pharma wave or will they be left beached? | LSE:AZN